3.86
+0.025(+0.65%)
Currency In USD
| Previous Close | 3.83 |
| Open | 3.84 |
| Day High | 3.9 |
| Day Low | 3.8 |
| 52-Week High | 4.03 |
| 52-Week Low | 0.69 |
| Volume | 925,871 |
| Average Volume | 6.93M |
| Market Cap | 761.48M |
| PE | -7.14 |
| EPS | -0.54 |
| Moving Average 50 Days | 3.06 |
| Moving Average 200 Days | 1.89 |
| Change | 0.03 |
If you invested $1000 in Esperion Therapeutics, Inc. (ESPR) 10 years ago, it would be worth $154.02 as of December 11, 2025 at a share price of $3.855. Whereas If you bought $1000 worth of Esperion Therapeutics, Inc. (ESPR) shares 5 years ago, it would be worth $132.25 as of December 11, 2025 at a share price of $3.855.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
GlobeNewswire Inc.
Nov 21, 2025 1:00 PM GMT
– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR)
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 19, 2025 1:00 PM GMT
ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET. The live webcast can
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
GlobeNewswire Inc.
Nov 18, 2025 12:00 PM GMT
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET®